Dare Bioscience, Inc. current report, 08 January 2015

Business Context and Reporting Period

This Form 8-K was filed by Cerulean Pharma Inc. on January 8, 2015. The filing reports the entry into a material definitive agreement involving a new term loan facility and equity investment, alongside the termination of a prior loan agreement. The company is a biopharmaceutical entity based in Cambridge, MA.

Key Financial Metrics and Transaction Details

  • New Debt Facility: Entered into a term loan facility with Hercules Technology Growth Capital, Inc. ("Hercules") for up to $26.0 million.
  • Initial Funding: The first tranche of $15.0 million was funded on the closing date.
  • Interest Rate: Floating rate equal to the greater of 7.30% or (7.30% + Prime Rate - 5.75%).
  • Repayment Terms: Interest-only payments monthly until December 31, 2015 (extendable based on milestones). Maturity date is July 1, 2018.
  • Final Payment: A final payment of 6.70% of the aggregate original principal amount is due at maturity or prepayment.
  • Equity Investment: Hercules purchased 135,501 shares of common stock for approximately $1.0 million at $7.38 per share.
  • Warrants: Hercules received a warrant to purchase 137,521 shares at an exercise price of $6.05 per share, exercisable until January 8, 2020.
  • Collateral: The loan is secured by a lien on substantially all company assets, excluding intellectual property (though rights to proceeds from IP are included).

Material Changes Versus Prior Period

  • Debt Refinancing: The company utilized approximately $3.6 million of the new loan proceeds to fully repay and terminate its existing loan agreement with Lighthouse Capital Partners VI, L.P.
  • Previous Debt Terms: The terminated Lighthouse facility had a principal limit of $10.0 million, an interest rate of 8.25%, and was secured by substantially all assets other than IP.
  • Liquidity Impact: The transaction replaced a smaller, higher-interest facility with a larger facility offering milestone-based tranches and an equity component.

Guidance, Outlook, and Risks

  • Future Funding Conditions:
    • Tranche 2 ($5.0 million): Available by December 15, 2015, subject to clinical milestones.
    • Tranche 3 ($6.0 million): Available between September 30 and December 15, 2015, contingent on the company raising at least $40.0 million in net cash proceeds from equity sales or strategic partnerships.
  • Prepayment Penalties: Prepayment charges apply: 3.0% within 12 months, 2.0% between 12-24 months, and 1.0% thereafter.
  • Events of Default: Include failure to pay, breach of covenants, material adverse effect, insolvency, or judgments on assets exceeding $250,000. Default triggers an additional 5.0% interest rate on past due amounts.
  • Right to Invest: Hercules holds a right to participate in up to $2.0 million of future private equity financings on the same terms as other investors.

Investor Verification Checklist

  • Verify the company's ability to meet the clinical milestones required to draw the second tranche of the loan.
  • Assess the likelihood of raising the required $40.0 million in equity or partnership proceeds to unlock the third tranche.
  • Review the impact of the 6.70% final payment obligation on the total cost of capital.
  • Confirm the dilution impact of the warrant (137,521 shares) and the potential additional warrant shares (34,380) if Tranche 3 is drawn.
  • Monitor compliance with financial covenants and restrictions on dividends and additional indebtedness.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.